ClinCapture to Provide Free EDC for Researchers Investigating COVID-19 Treatment
ClinCapture, Inc., a provider for Electronic Data Capture (EDC) systems and eClinical solutions, announced that it will begin offering EDC at no cost for specific clinical trials investigating COVID-19 Coronavirus. The decision to offer free EDC for BioPharma and Diagnostic companies conducting COVID-19 clinical trials was announced after the World Health Organization issued a statement that the confirmed number of COVID-19 cases has surpassed 100,000 globally.
ClinCapture is inspired by the response time, organization, and dedication to find solutions for COVID-19 demonstrated within the clinical research industry and would like to help these companies by offering free EDC for their trials. ClinCapture will be providing its Captivate EDC through the philanthropic Weidley's Wish program which normally provides EDC to non-profit organizations conducting Rare Disease/Orphan Disease trials.
"We are in a unique position in a unique point in history," said ClinCapture CEO Scott Weidley. "Our commitment to act now will have a dramatic effect on our ability to help in the future."
ClinCapture's Captivate EDC is a fully validated, cloud-hosted system designed to offer researchers more insight into their clinical data in order to bring treatments to market faster.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
